title: Aidi injection combined with CHOP chemotherapy regimen in the treatment of malignant lymphoma: A meta-analysis based on randomized controlled trials.
abstract: OBJECTIVE
  The aim of this study was to evaluate the clinical efficacy of Aidi injection combined with CHOP chemotherapy regimen in the treatment of malignant lymphoma.
  
  
  METHODS
  We made an electronic search in the database of Wanfang, CNKI, and PubMed. All the clinical studies related to Aidi injection combined with CHOP chemotherapy regimen in the treatment of malignant lymphoma were screened and reviewed. The combined objective response rate (ORR), life quality improvement, and hematological toxicity were pooled by random- or fixed-effect model according to the heterogeneity across the included study. Moreover, the publication bias was evaluated by Begg's funnel plot and Egger's line regression test.
  
  
  RESULTS
  Eight prospective clinical trials with 513 subjects (273 in the Aidi injection plus CHOP group and 240 in the CHOP group) were included in this meta-analysis. The pooled results showed that Aidi injection combined with CHOP chemotherapy regimen can significantly improve the ORR (odds ratio [OR] =1.68, 95% confidence interval [CI]: 1.09-2.60, P < 0.05), improve the life quality (OR = 3.32, 95% CI: 1.97-5.58, P < 0.05), and decrease the risk of developing leukopenia (OR = 0.25, 95% CI: 0.17-0.39, P < 0.05) and thrombocytopenia (OR = 0.34, 95% CI: 0.22-0.53, P < 0.05).
  
  
  CONCLUSIONS
  With the present evidence, Aidi injection combined with CHOP chemotherapy regimen can improve the treatment response and quality of life and decrease the risk of developing severe leukopenia or thrombocytopenia.
authors.affiliation: Department of Hematology, The People's Hospital of Liushui (The 6th Affiliated Hospital of Wenzhou Medican University), Lishui 323000, Zhejiang Province, China.
authors.forename: Xiaoli
authors.initials: X
authors.lastname: Wang
authors.affiliation: Department of Hematology, The People's Hospital of Liushui (The 6th Affiliated Hospital of Wenzhou Medican University), Lishui 323000, Zhejiang Province, China.
authors.forename: Weimei
authors.initials: W
authors.lastname: Jin
authors.affiliation: Department of Hematology, The People's Hospital of Liushui (The 6th Affiliated Hospital of Wenzhou Medican University), Lishui 323000, Zhejiang Province, China.
authors.forename: Bingmu
authors.initials: B
authors.lastname: Fang
authors.affiliation: Department of Hematology, The People's Hospital of Liushui (The 6th Affiliated Hospital of Wenzhou Medican University), Lishui 323000, Zhejiang Province, China.
authors.forename: Jinhong
authors.initials: J
authors.lastname: Jiang
authors.affiliation: Department of Hematology, The People's Hospital of Liushui (The 6th Affiliated Hospital of Wenzhou Medican University), Lishui 323000, Zhejiang Province, China.
authors.forename: Min
authors.initials: M
authors.lastname: Liu
authors.affiliation: Department of Hematology, The People's Hospital of Liushui (The 6th Affiliated Hospital of Wenzhou Medican University), Lishui 323000, Zhejiang Province, China.
authors.forename: Yifen
authors.initials: Y
authors.lastname: Lan
authors.affiliation: Department of Hematology, The People's Hospital of Liushui (The 6th Affiliated Hospital of Wenzhou Medican University), Lishui 323000, Zhejiang Province, China.
authors.forename: Zhigang
authors.initials: Z
authors.lastname: Qu
authors.affiliation: Department of Hematology, The People's Hospital of Liushui (The 6th Affiliated Hospital of Wenzhou Medican University), Lishui 323000, Zhejiang Province, China.
authors.forename: Guangli
authors.initials: G
authors.lastname: Ma
authors.affiliation: Department of Hematology, The People's Hospital of Liushui (The 6th Affiliated Hospital of Wenzhou Medican University), Lishui 323000, Zhejiang Province, China.
authors.forename: Yu
authors.initials: Y
authors.lastname: Jiang
authors.affiliation: Department of Hematology, The People's Hospital of Liushui (The 6th Affiliated Hospital of Wenzhou Medican University), Lishui 323000, Zhejiang Province, China.
authors.forename: Yonghua
authors.initials: Y
authors.lastname: Liu
authors.affiliation: Department of Hematology, The People's Hospital of Liushui (The 6th Affiliated Hospital of Wenzhou Medican University), Lishui 323000, Zhejiang Province, China.
authors.forename: Yuxiao
authors.initials: Y
authors.lastname: Zeng
authors.affiliation: Department of Hematology, The People's Hospital of Liushui (The 6th Affiliated Hospital of Wenzhou Medican University), Lishui 323000, Zhejiang Province, China.
authors.forename: Xiaoqiu
authors.initials: X
authors.lastname: Wang
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D004365:Drugs, Chinese Herbal / Q000008:administration & dosage*; D006801:Humans; D008223:Lymphoma / Q000188:drug therapy*; D016017:Odds Ratio; D011241:Prednisone / Q000627:therapeutic use; D011788:Quality of Life; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome; D014750:Vincristine / Q000627:therapeutic use
chemical_list: D004365:Drugs, Chinese Herbal; C517300:aidi herbal drug; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone